All articles by GlobalData 

  1. Female infertility drug market set to reach $2.5bn by 2028 in the 7MM, says GlobalData

    Female infertility, defined as the inability to conceive a child after one year of unprotected intercourse, is a complex disorder…
    Read More…

    28 Nov
  2. The Crohn’s disease market will continue to rise, dominated by the US, says GlobalData

    Crohn’s disease is an inflammatory bowel condition that comprises two chronic autoimmune diseases. Both Crohn’s disease and ulcerative colitis cause…
    Read More…

    28 Nov
  3. Deal making trends in the pharmaceutical industry in the first half of 2019

    The pharmaceutical industry is integral to global healthcare and is also one of the world’s most valuable industries. The development…
    Read More…

    25 Nov
  4. Twitter round-up: Measles outbreak in New Zealand trends in October 2019

    Pharmaceutical Technology lists ten of the top tweets on infectious diseases in October 2019, based on data from GlobalData’s Influencer…
    Read More…

    20 Nov
  5. Gene therapy development expected to pick up pace, says GlobalData

    Genes are what make human beings the people they are, with genetic codes defining key characteristics such as eye colour,…
    Read More…

    18 Nov
  6. Clinical trials continue to develop for growth hormone deficiency, says GlobalData

    Growth hormone deficiency (GHD) is a condition caused by a lack of growth hormone in the human body. The condition…
    Read More…

    18 Nov
  7. Myelodysplastic syndrome cases are under-reported in the US national registry

    Myelodysplastic syndromes (MDS) are a group of rare and diverse hematopoietic malignancies characterised by molecular abnormalities, causing bone marrow failure…
    Read More…

    13 Nov
  8. Oncology: Breast cancer leads Twitter mentions in Q3 2019

    Pharmaceutical Technology lists the top five terms tweeted in oncology in Q3 2019, based on data from GlobalData’s Influencer Platform….
    Read More…

    4 Nov
  9. IDWeek 2019: Climate change poses risks for the spread of infectious diseases

    On 4 October, healthcare practitioners and stakeholders gathered at IDWeek 2019 in Washington DC to discuss issues related to the…
    Read More…

    8 Oct
  10. Novartis’ Zolgensma has Phase I trial planned for 2020 to evaluate SMA infants who present neutralising antibodies, source says

    Novartis (SIX:NOVN) has a Phase I Zolgensma (onasemnogene abeparvovec-xioi) study planned to initiate in 2020 for infants with spinal muscular…
    Read More…

    31 Jul
Close
Close
Close

Go Top